Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients

Georgiades, Anastasia; Davis, Vicki G.; Atkins, Alexandra S.; Khan, Anzalee; Walker, Trina M.; Loebel, Antony; Haig, George M.; Hilt, Dana; Dunayevich, Eduardo; Umbricht, Daniel; Sand, Michael; Keefe, Richard S.E.

doi:10.1016/j.schres.2017.03.040

Cited by 36 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, for precise assessment of clinical and cognitive statuses, we used a validated instrument and its cognitive sub-domains, along with a delta value proportional to its initial value. MCCB, a cognitive battery comprising assessments of seven cognitive domains that was used in the present study, is considered the FDA gold standard outcome measure of cognitive treatment effects in clinical trials involving patients with schizophrenia, 27,28 the PANSS is a frequently used scale with three subscales that separately assess positive, negative, and general symptoms. 26 The Δclozapine/NDMC ratio had a significant impact on attention/vigilance performance.…”

Section: Discussionmentioning

confidence: 99%

“…26 Cognition was assessed using the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB), which was developed to assess cognitive treatment effects in clinical trials involving patients with schizophrenia; it is considered the Food and Drug Administration (FDA) gold standard outcome measure for that purpose. 27,28 The T-scores for each cognitive domain, standardized and corrected for age and sex, were used as individual outcome measures. 29 The overall composite score was the standardized total of scores for the seven domains.…”

Section: Clinical and Cognitive Assessmentsmentioning

confidence: 99%

See 1 more Smart Citation

Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia

Park

Kim

2020

Psychiatry Investig

View full text Add to dashboard Cite

Objective The clozapine/N-desmethylclozapine (NDMC) ratio is proposed to be used as a predictor of cognitive performance in clozapine-treated patients, as its principal metabolite, NDMC, has an opposite action with clozapine on the cholinergic system. The aim of this study is to determine whether clozapine has influence on cognitive performance in accordance with changes in the clozapine/NDMC in patients with schizophrenia.Methods The data of fifteen patients with schizophrenia, who had initial and follow-up assessments after starting clozapine treatment, were retrospectively collected. The assessments included clinical scale, cognitive battery, and pharmacological data including plasma concentrations of clozapine and NDMC. The data were analyzed with Pearson correlation and stepwise multiple regression analyses.Results ΔAttention/vigilance, Δsocial cognition, and Δcomposite score had a significant correlation with Δclozapine/NDMC ratio, while ΔWorking memory had correlation with Δclozapine concentration and ΔNDMC concentration, and Δsocial cognition had association with Δclozapine concentration. Multiple regression analysis showed that Δattention/vigilance had negative association with Δclozapine/NDMC ratio, Δworking memory had negative relation with Δclozapine concentration, and that Δsocial cognition had negative association with Δclozapine concentration.Conclusion This finding implicates that lowering the clozapine/NDMC ratio could enhance cognition in patients with schizophrenia treated with clozapine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Clinical and Cognitive Assessmentsmentioning

confidence: 99%

Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia

Park

Kim

2020

Psychiatry Investig

View full text Add to dashboard Cite

show abstract

“…Running an outlier test with a cutoff of 3.0 SD led to the detection of two SCZ patients and no HC. As patients with schizophrenia can perform 3.0 SD below normative standards on individual tests ( 16 ), this finding does not reflect a major concern.…”

Section: Studymentioning

confidence: 90%

“…For instance, in the first SCOPE study ( 15 ), the most impaired social cognitive domain had an effect size for comparison with the performance of HC of d = −1.05, with mean effect size across 10 measures of d = −0.69. In a study of 2,616 patients with schizophrenia ( 16 ), the least impaired neurocognitive domain had an effect size of d = −0.99, the mean of 10 different neurocognitive tests was d = −1.7, and a weighted composite had an effect size of d = −2.2. Thus, substantially impaired neurocognitive performance might lead to challenges in performing other cognitively demanding tests, even if their demands appear to be primarily social in nature.…”

Section: Introductionmentioning

confidence: 99%

Social Cognition and Neurocognition in Schizophrenia and Healthy Controls: Intercorrelations of Performance and Effects of Manipulations Aimed at Increasing Task Difficulty

et al. 2018

View full text Add to dashboard Cite

Social cognition (SC) and neurocognition appear to predict different aspects of functional outcome in people with schizophrenia. However, the correlations between performance on these domains have not been tested extensively and compared cross-diagnostically with healthy controls. Further, some social cognitive measures appeared to have potential ceiling effects, particularly for healthy people, in previous research, so increasing their difficulty is of interest. In this paper we report on two studies wherein we examined the correlations between neurocognitive ability and performance on SC tests. In the first study the correlations between measures of social perception, emotion processing, and theory of mind and performance on a brief neuropsychological (NP) assessment were examined in 179 schizophrenia (SCZ) patients and 104 healthy controls (HC). In the second study, we instructed participants to perform a subset of the tasks as rapidly as possible in order to increase task difficulty, and we examined the effects of those instructions on task difficulty, task psychometrics, and correlations between SC and NP tests in 218 SCZ patients and 154 HC. In the first study, both HC and SCZ manifested a domain specific pattern of correlation between NP and SC test performance. Controlling for group differences in NP performance did not eliminate SC performance differences between the groups. In the second study, no differences in task performance, intercorrelations other SC tests, or test-retest stability were induced by the difficulty manipulation in the samples who performed the tasks with speed demands compared to the performance of the previous sample. These data suggest that simple manipulations aimed at increasing task difficulty may not have the desired effect and that despite consistent correlations between SC and NP test performance, impairments in social cognitive functioning are not fully explained by NP performance deficits.

show abstract

“…The neuropsychological test battery consisted of several tests, chosen according to the MATRICS Consensus Cognitive Battery (Nuechterlein et al, ). The focus in our examination was on three cognitive domains, recently shown to explain about 86% of the variance for the composed cognitive score in stable patients with schizophrenia (Georgiades et al, ): Speed of processing (Trail Making Test, Part A, the coding task from the Wechsler Intelligence Scale [WAIS‐IV]), working memory (Letter‐Number Span test and Corsi block‐tapping task) and visual learning (Rey Visual Design Learning Test).…”

Section: Methodsmentioning

confidence: 99%

mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia

Brambilla

Veselinović

Rajkumar

et al. 2020

Human Brain Mapping

View full text Add to dashboard Cite

Consistent findings postulate disturbed glutamatergic function (more specifically a hypofunction of the ionotropic NMDA receptors) as an important pathophysiologic mechanism in schizophrenia. However, the role of the metabotropic glutamatergic receptors type 5 (mGluR5) in this disease remains unclear. In this study, we investigated their significance (using [11C]ABP688) for psychopathology and cognition in male patients with chronic schizophrenia and healthy controls. In the patient group, lower mGluR5 binding potential (BPND) values in the left temporal cortex and caudate were associated with higher general symptom levels (negative and depressive symptoms), lower levels of global functioning and worse cognitive performance. At the same time, in both groups, mGluR5 BPND were significantly lower in smokers (F[27,1] = 15.500; p = .001), but without significant differences between the groups. Our findings provide support for the concept that the impaired function of mGluR5 underlies the symptoms of schizophrenia. They further supply a new perspective on the complex relationship between tobacco addiction and schizophrenia by identifying glutamatergic neurotransmission—in particularly mGluR5—as a possible connection to a shared vulnerability.

show abstract

Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients

Cited by 36 publications

References 23 publications

Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia

Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia

Social Cognition and Neurocognition in Schizophrenia and Healthy Controls: Intercorrelations of Performance and Effects of Manipulations Aimed at Increasing Task Difficulty

mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia

Contact Info

Product

Resources

About